Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
J Qin, L Xue, A Hao, X Guo, T Jiang, Y Ni, S Liu… - Nature medicine, 2024 - nature.com
Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus
chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA …
chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA …
Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal …
K Li, H Yan, T Ke - International Journal of Surgery, 2024 - journals.lww.com
We would like to express our deepest gratitude to Yunnan Cancer Hospital for their
unwavering support and for providing the necessary resources to conduct this research. We …
unwavering support and for providing the necessary resources to conduct this research. We …
[HTML][HTML] Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world …
Y Guo, X Xu, T Wang, Y Liu, D Gu, Y Fang… - International …, 2024 - Elsevier
Background This study aims to analyze the efficacy and safety of neoadjuvant programmed
cell death-1 (PD-1) blockade plus chemotherapy in real-world applications. Additionally, we …
cell death-1 (PD-1) blockade plus chemotherapy in real-world applications. Additionally, we …
Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma
H Lv, F Zhang, C Huang, S Xu, J Li, B Sun… - Journal of Cancer …, 2024 - Springer
Purpose Neoadjuvant chemotherapy (NCT) is the standard preoperative treatment for
resectable locally advanced esophageal squamous cell carcinoma (ESCC). Some studies …
resectable locally advanced esophageal squamous cell carcinoma (ESCC). Some studies …
[HTML][HTML] Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and …
L Liu, Y Liu, Y Ding, J Han, Q Wang… - Journal of Thoracic …, 2024 - ncbi.nlm.nih.gov
Background Immunochemotherapy was an emerging neoadjuvant treatment mode that can
potentially benefit patients with esophageal carcinoma, but its synergistic mechanism and …
potentially benefit patients with esophageal carcinoma, but its synergistic mechanism and …
Long-term outcomes of smoker and drinker with oesophageal squamous cell carcinoma after oesophagectomy: a large-scale propensity score matching analysis
K Li, S Lu, C Li, W He, K Du, K Liu… - BMJ Open …, 2024 - bmjopengastro.bmj.com
Background Oesophageal squamous cell carcinoma (OSCC) poses a considerable health
burden, particularly in regions such as East Asia. This study aims to investigate the long …
burden, particularly in regions such as East Asia. This study aims to investigate the long …
Is neoadjuvant chemotherapy combined with immunotherapy really better than neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma …
K Li, J Yang, Y Huang - The Journal of Thoracic and Cardiovascular …, 2024 - jtcvs.org
Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy
requires editors and reviewers to disclose conflicts of interest and to decline handling or …
requires editors and reviewers to disclose conflicts of interest and to decline handling or …
[引用][C] Commentary: Is neoadjuvant chemoimmunotherapy for esophageal cancer the next great frontier?
RM Lee, MB Antonoff - The Journal of Thoracic and Cardiovascular Surgery, 2024 - jtcvs.org
compared outcomes in patients with squamous cell carcinoma of the esophagus who
received neoadjuvant chemoradiotherapy with those who received neoadjuvant …
received neoadjuvant chemoradiotherapy with those who received neoadjuvant …